Cargando…
Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study
BACKGROUND: Synthesized fatty acids (FAs) from de novo lipogenesis may affect cardiometabolic health, but longitudinal associations between serially measured de novo lipogenesis–related fatty acid biomarkers and mortality or cardiovascular disease (CVD) are not well established. METHODS AND RESULTS:...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915264/ https://www.ncbi.nlm.nih.gov/pubmed/31711385 http://dx.doi.org/10.1161/JAHA.119.012881 |
_version_ | 1783479975619330048 |
---|---|
author | Lai, Heidi T.M. de Oliveira Otto, Marcia C. Lee, Yujin Wu, Jason H.Y. Song, Xiaoling King, Irena B. Psaty, Bruce M. Lemaitre, Rozenn N. McKnight, Barbara Siscovick, David S. Mozaffarian, Dariush |
author_facet | Lai, Heidi T.M. de Oliveira Otto, Marcia C. Lee, Yujin Wu, Jason H.Y. Song, Xiaoling King, Irena B. Psaty, Bruce M. Lemaitre, Rozenn N. McKnight, Barbara Siscovick, David S. Mozaffarian, Dariush |
author_sort | Lai, Heidi T.M. |
collection | PubMed |
description | BACKGROUND: Synthesized fatty acids (FAs) from de novo lipogenesis may affect cardiometabolic health, but longitudinal associations between serially measured de novo lipogenesis–related fatty acid biomarkers and mortality or cardiovascular disease (CVD) are not well established. METHODS AND RESULTS: We investigated longitudinal associations between de novo lipogenesis–related fatty acids with all‐cause mortality, cause‐specific mortality, and incident CVD among 3869 older US adults, mean (SD) age 75 (5) years and free of prevalent CVD at baseline. Levels of plasma phospholipid palmitic (16:0), palmitoleic (16:1n‐7), stearic (18:0), oleic acid (18:1n‐9), and other risk factors were serially measured at baseline, 6 years, and 13 years. All‐cause mortality, cause‐specific mortality, and incident fatal and nonfatal CVD were centrally adjudicated. Risk was assessed in multivariable‐adjusted Cox models with time‐varying FAs and covariates. During 13 years, median follow‐up (maximum 22.4 years), participants experienced 3227 deaths (1131 CVD, 2096 non‐CVD) and 1753 incident CVD events. After multivariable adjustment, higher cumulative levels of 16:0, 16:1n‐7, and 18:1n‐9 were associated with higher all‐cause mortality, with extreme‐quintile hazard ratios (95% CIs) of 1.35 (1.17–1.56), 1.40 (1.21–1.62), and 1.56 (1.35–1.80), respectively, whereas higher levels of 18:0 were associated with lower mortality (hazard ratio=0.76; 95% CI=0.66–0.88). Associations were generally similar for CVD mortality versus non‐CVD mortality, as well as total incident CVD. Changes in levels of 16:0 were positively, and 18:0 inversely, associated with all‐cause mortality (hazard ratio=1.23, 95% CI=1.08–1.41; and hazard ratio=0.78, 95% CI=0.68–0.90). CONCLUSIONS: Higher long‐term levels of 16:0, 16:1n‐7, and 18:1n‐9 and changes in 16:0 were positively, whereas long‐term levels and changes in 18:0 were inversely, associated with all‐cause mortality in older adults. |
format | Online Article Text |
id | pubmed-6915264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69152642019-12-23 Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study Lai, Heidi T.M. de Oliveira Otto, Marcia C. Lee, Yujin Wu, Jason H.Y. Song, Xiaoling King, Irena B. Psaty, Bruce M. Lemaitre, Rozenn N. McKnight, Barbara Siscovick, David S. Mozaffarian, Dariush J Am Heart Assoc Original Research BACKGROUND: Synthesized fatty acids (FAs) from de novo lipogenesis may affect cardiometabolic health, but longitudinal associations between serially measured de novo lipogenesis–related fatty acid biomarkers and mortality or cardiovascular disease (CVD) are not well established. METHODS AND RESULTS: We investigated longitudinal associations between de novo lipogenesis–related fatty acids with all‐cause mortality, cause‐specific mortality, and incident CVD among 3869 older US adults, mean (SD) age 75 (5) years and free of prevalent CVD at baseline. Levels of plasma phospholipid palmitic (16:0), palmitoleic (16:1n‐7), stearic (18:0), oleic acid (18:1n‐9), and other risk factors were serially measured at baseline, 6 years, and 13 years. All‐cause mortality, cause‐specific mortality, and incident fatal and nonfatal CVD were centrally adjudicated. Risk was assessed in multivariable‐adjusted Cox models with time‐varying FAs and covariates. During 13 years, median follow‐up (maximum 22.4 years), participants experienced 3227 deaths (1131 CVD, 2096 non‐CVD) and 1753 incident CVD events. After multivariable adjustment, higher cumulative levels of 16:0, 16:1n‐7, and 18:1n‐9 were associated with higher all‐cause mortality, with extreme‐quintile hazard ratios (95% CIs) of 1.35 (1.17–1.56), 1.40 (1.21–1.62), and 1.56 (1.35–1.80), respectively, whereas higher levels of 18:0 were associated with lower mortality (hazard ratio=0.76; 95% CI=0.66–0.88). Associations were generally similar for CVD mortality versus non‐CVD mortality, as well as total incident CVD. Changes in levels of 16:0 were positively, and 18:0 inversely, associated with all‐cause mortality (hazard ratio=1.23, 95% CI=1.08–1.41; and hazard ratio=0.78, 95% CI=0.68–0.90). CONCLUSIONS: Higher long‐term levels of 16:0, 16:1n‐7, and 18:1n‐9 and changes in 16:0 were positively, whereas long‐term levels and changes in 18:0 were inversely, associated with all‐cause mortality in older adults. John Wiley and Sons Inc. 2019-11-12 /pmc/articles/PMC6915264/ /pubmed/31711385 http://dx.doi.org/10.1161/JAHA.119.012881 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Lai, Heidi T.M. de Oliveira Otto, Marcia C. Lee, Yujin Wu, Jason H.Y. Song, Xiaoling King, Irena B. Psaty, Bruce M. Lemaitre, Rozenn N. McKnight, Barbara Siscovick, David S. Mozaffarian, Dariush Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title | Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title_full | Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title_fullStr | Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title_full_unstemmed | Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title_short | Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause‐Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study |
title_sort | serial plasma phospholipid fatty acids in the de novo lipogenesis pathway and total mortality, cause‐specific mortality, and cardiovascular diseases in the cardiovascular health study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915264/ https://www.ncbi.nlm.nih.gov/pubmed/31711385 http://dx.doi.org/10.1161/JAHA.119.012881 |
work_keys_str_mv | AT laiheiditm serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT deoliveiraottomarciac serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT leeyujin serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT wujasonhy serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT songxiaoling serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT kingirenab serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT psatybrucem serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT lemaitrerozennn serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT mcknightbarbara serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT siscovickdavids serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy AT mozaffariandariush serialplasmaphospholipidfattyacidsinthedenovolipogenesispathwayandtotalmortalitycausespecificmortalityandcardiovasculardiseasesinthecardiovascularhealthstudy |